What is the dosing range for Tirzepatide?

Tirzepatide is typically dosed at 2.5mg (low), 10mg (moderate), or 15mg (high) mg, administered Once weekly subcutaneous injection. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of Tirzepatide?

Reported side effects of Tirzepatide include: Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation, Decreased appetite, Injection site reactions, Fatigue, Dyspepsia, Risk of thyroid C-cell tumors (rodent data; human risk unclear — contraindicated with MEN2 or medullary thyroid carcinoma history).

GLP-1

Tirzepatide

Also known as: LY3298176, Mounjaro, Zepbound

Tirzepatide (Mounjaro/Zepbound) is FDA-approved for type 2 diabetes and obesity under physician supervision. Research-grade tirzepatide is for laboratory use only. Not for unsupervised self-administration. Consult a licensed physician.

📚 Content aggregated from:3 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.

Research Summary

The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.

Dosing Range

low

2.5mg

moderate

10mg

high

15mg

Units: mg · Frequency: Once weekly subcutaneous injection

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injection (abdomen, thigh, or upper arm)

Reconstitution Notes

Available as pre-filled auto-injector pens (KwikPen). Research-grade tirzepatide is lyophilized powder — reconstitute with bacteriostatic water. Common concentration: 5mg/mL. Stable 28 days refrigerated after reconstitution.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Nausea (most common, especially during titration)
Vomiting
Diarrhea
Constipation
Decreased appetite
Injection site reactions
Fatigue
Dyspepsia
Risk of thyroid C-cell tumors (rodent data; human risk unclear — contraindicated with MEN2 or medullary thyroid carcinoma history)

Research Papers

3 peer-reviewed sources

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

New England Journal of Medicine2022

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

New England Journal of Medicine2021

Dual GIP and GLP-1 Receptor Agonist Tirzepatide — A Review

Drugs2022

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Tirzepatide

Active community sharing dosing protocols, side effect management, and weight loss progress data.

View original thread

r/Semaglutide

Cross-community comparisons between tirzepatide and semaglutide outcomes.

View original thread

Overview

Tirzepatide represents the first approved dual incretin receptor agonist — a class called "twincretins." By targeting both GIP and GLP-1 receptors simultaneously, it achieves synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite that exceed what either pathway alone can produce.

Mechanism: Dual Incretin Action

GLP-1 receptor activation (shared with semaglutide):

Suppresses appetite via hypothalamic signaling
Slows gastric emptying
Stimulates glucose-dependent insulin release
Suppresses glucagon

GIP receptor activation (unique to tirzepatide):

Potentiates insulin secretion synergistically with GLP-1
Acts on adipose tissue to improve fat metabolism
May reduce GLP-1-associated nausea (GIP has opposing effects on the nausea center)
Improves lipid metabolism and adiponectin levels

The combination produces weight loss superior to GLP-1 monotherapy at equivalent tolerability.

Clinical Trial Highlights

| Trial | Comparator | Weight Loss (Tirzepatide 15mg) | |-------|-----------|-------------------------------| | SURMOUNT-1 | Placebo | −22.5% body weight | | SURMOUNT-5 | Semaglutide 2.4mg | ~47% more weight loss | | SURPASS-2 | Semaglutide 1mg | −5.5% additional HbA1c reduction |

Titration Protocol

Standard titration to minimize GI side effects:

Weeks 1–4: 2.5mg/week
Weeks 5–8: 5mg/week
Weeks 9–12: 7.5mg/week (maintenance for many)
Weeks 13–16: 10mg/week (optional escalation)
Weeks 17–20: 12.5mg/week
Week 21+: 15mg/week (max dose)

Slower titration (doubling time every 8 weeks instead of 4) significantly reduces GI side effects.

vs. Semaglutide

Tirzepatide consistently outperforms semaglutide in head-to-head trials for both weight loss and glycemic control. The GIP component is believed responsible for the additional efficacy. Tolerability is similar between the two; some users report less nausea with tirzepatide due to GIP's partial anti-emetic effects.